STOCK TITAN

[Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported the automatic sale of 8,828 shares of common stock to satisfy tax withholding related to the vesting of restricted stock units. The weighted average price reported for the sales was $14.5751, with execution prices ranging from $14.355 to $15.075. After the transaction, the filing shows the reporting person beneficially owns 148,141 shares. The filing notes the sales were automatic to cover tax obligations and not at the reporting person's discretion.

Gina Mazzariello, Direttrice Legale di Amylyx Pharmaceuticals, Inc. (AMLX), ha riferito la vendita automatica di 8.828 azioni ordinarie per soddisfare le ritenute fiscali relative al vesting delle unità di azioni vincolate. Il prezzo medio ponderato riportato per le vendite era di $14,5751, con prezzi di esecuzione compresi tra $14,355 e $15,075. Dopo la transazione, la persona che presenta la relazione possiede beneficiamente 148.141 azioni. La relazione nota che le vendite sono state automatiche per coprire gli obblighi fiscali e non sono avvenute a discrezione della persona che presenta la relazione.

Gina Mazzariello, Directora Jurídica de Amylyx Pharmaceuticals, Inc. (AMLX), informó la venta automática de 8.828 acciones ordinarias para satisfacer las retenciones fiscales relacionadas con el vesting de las unidades de acciones restringidas. El precio medio ponderado informado para las ventas fue de $14,5751, con precios de ejecución que oscilaron entre $14,355 y $15,075. Después de la transacción, la persona que presentó el informe posee beneficiosamente 148,141 acciones. El informe señala que las ventas fueron automáticas para cubrir las obligaciones fiscales y no fueron a discreción de la persona que presenta el informe.

지나 마자리엘로, Amylyx Pharmaceuticals, Inc. (AMLX)의 최고 법률 책임자(CLO)로서 제한 주식 단위의 vesting과 관련된 세금 원천징수를 충당하기 위해 자동으로 매각된 8,828주를 보고했습니다. 매매에 보고된 가중 평균 가격은 $14,5751였으며 체결가 범위는 $14,355에서 $15,075였습니다. 거래 후 보고서는 보고자의 보유 주식이 148,141주로 증가했음을 나타냅니다. 보고서는 이 매매가 신고인의 재량이 아닌 세무 의무를 충당하기 위해 자동으로 이루어졌다고 기재하고 있습니다.

Gina Mazzariello, Directrice juridique de Amylyx Pharmaceuticals, Inc. (AMLX), a signalé la vente automatique de 8 828 actions ordinaires pour satisfaire les retenues d'impôt liées à la vesting des unités d'actions restreintes. Le prix moyen pondéré rapporté pour les ventes était de $14,5751, avec des prix d'exécution allant de $14,355 à $15,075. Après la transaction, la personne qui a déposé le dossier détient bénéficairement 148 141 actions. Le dossier note que les ventes étaient automatiques pour couvrir les obligations fiscales et non à la discrétion de la personne qui a déposé le dossier.

Gina Mazzariello, Chief Legal Officer von Amylyx Pharmaceuticals, Inc. (AMLX), meldete den automatischen Verkauf von 8.828 Stammaktien zur Begleichung von Steuerabzügen im Zusammenhang mit dem Vesting von Restricted Stock Units. Der gemeldete gewichtete Durchschnittspreis für die Verkäufe betrug $14,5751, mit Ausführungspreisen von $14,355 bis $15,075. Nach der Transaktion besitzt die meldende Person vorteilhaft 148.141 Aktien. Die Einreichung stellt fest, dass die Verkäufe automatisch erfolgt seien, um Steuerverpflichtungen zu decken und nicht nach Ermessen der meldenden Person.

جينا مازارييلو، المسؤولة القانونية الأولى في Amylyx Pharmaceuticals, Inc. (AMLX)، أفادت ببيع تلقائي لـ 8,828 أسهم عادية لتلبية الخصومات الضريبية المتعلقة بتوزيع وحدات الأسهم المقيدة vesting. كان السعر المتوسط المرجح المبلغ عنه للبيعات $14,5751، مع نطاق أسعار التنفيذ من $14,355 إلى $15,075. بعد المعاملة، تظهر الوثيقة أن الشخص المبلغ يمتلك بشكل مستفيد 148,141 سهماً. وتلاحظ الوثيقة أن المبيعات كانت تلقائية لتغطية الالتزامات الضريبية وليست وفقًا لتقدير الشخص المبلغ.

Gina MazzarielloAmylyx Pharmaceuticals, Inc. (AMLX) 的首席法务官报告了自动出售 8,828 股普通股,以满足与限制性股票单位归属相关的税款代扣。报告的出售加权平均价格为 $14,5751,成交价格区间为 $14,355$15,075。交易完成后,申报人实际拥有 148,141 股。申报指出,这些出售是为覆盖税务义务而自动进行,并非申报人自行决定。

Positive
  • None.
Negative
  • None.

Gina Mazzariello, Direttrice Legale di Amylyx Pharmaceuticals, Inc. (AMLX), ha riferito la vendita automatica di 8.828 azioni ordinarie per soddisfare le ritenute fiscali relative al vesting delle unità di azioni vincolate. Il prezzo medio ponderato riportato per le vendite era di $14,5751, con prezzi di esecuzione compresi tra $14,355 e $15,075. Dopo la transazione, la persona che presenta la relazione possiede beneficiamente 148.141 azioni. La relazione nota che le vendite sono state automatiche per coprire gli obblighi fiscali e non sono avvenute a discrezione della persona che presenta la relazione.

Gina Mazzariello, Directora Jurídica de Amylyx Pharmaceuticals, Inc. (AMLX), informó la venta automática de 8.828 acciones ordinarias para satisfacer las retenciones fiscales relacionadas con el vesting de las unidades de acciones restringidas. El precio medio ponderado informado para las ventas fue de $14,5751, con precios de ejecución que oscilaron entre $14,355 y $15,075. Después de la transacción, la persona que presentó el informe posee beneficiosamente 148,141 acciones. El informe señala que las ventas fueron automáticas para cubrir las obligaciones fiscales y no fueron a discreción de la persona que presenta el informe.

지나 마자리엘로, Amylyx Pharmaceuticals, Inc. (AMLX)의 최고 법률 책임자(CLO)로서 제한 주식 단위의 vesting과 관련된 세금 원천징수를 충당하기 위해 자동으로 매각된 8,828주를 보고했습니다. 매매에 보고된 가중 평균 가격은 $14,5751였으며 체결가 범위는 $14,355에서 $15,075였습니다. 거래 후 보고서는 보고자의 보유 주식이 148,141주로 증가했음을 나타냅니다. 보고서는 이 매매가 신고인의 재량이 아닌 세무 의무를 충당하기 위해 자동으로 이루어졌다고 기재하고 있습니다.

Gina Mazzariello, Directrice juridique de Amylyx Pharmaceuticals, Inc. (AMLX), a signalé la vente automatique de 8 828 actions ordinaires pour satisfaire les retenues d'impôt liées à la vesting des unités d'actions restreintes. Le prix moyen pondéré rapporté pour les ventes était de $14,5751, avec des prix d'exécution allant de $14,355 à $15,075. Après la transaction, la personne qui a déposé le dossier détient bénéficairement 148 141 actions. Le dossier note que les ventes étaient automatiques pour couvrir les obligations fiscales et non à la discrétion de la personne qui a déposé le dossier.

Gina Mazzariello, Chief Legal Officer von Amylyx Pharmaceuticals, Inc. (AMLX), meldete den automatischen Verkauf von 8.828 Stammaktien zur Begleichung von Steuerabzügen im Zusammenhang mit dem Vesting von Restricted Stock Units. Der gemeldete gewichtete Durchschnittspreis für die Verkäufe betrug $14,5751, mit Ausführungspreisen von $14,355 bis $15,075. Nach der Transaktion besitzt die meldende Person vorteilhaft 148.141 Aktien. Die Einreichung stellt fest, dass die Verkäufe automatisch erfolgt seien, um Steuerverpflichtungen zu decken und nicht nach Ermessen der meldenden Person.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Mazzariello Gina

(Last) (First) (Middle)
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET

(Street)
CAMBRIDGE MA 02141

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/30/2025 S(1) 8,828(1) D $14.5751(2) 148,141 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.355 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
/s/ Joshua B. Cohen, as Attorney in Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Gina Mazzariello report on Form 4 for AMLX?

The Form 4 reports the automatic sale of 8,828 shares to cover tax withholding from vested restricted stock units.

At what price were the AMLX shares sold in the reported transaction?

The filing reports a weighted average sale price of $14.5751, with individual sale prices ranging from $14.355 to $15.075.

How many AMLX shares does the reporting person beneficially own after the sale?

The filing shows beneficial ownership of 148,141 shares following the reported transaction.

Why were the AMLX shares sold according to the Form 4?

The filing states the shares were sold automatically to satisfy tax withholding obligations arising from the vesting of restricted stock units, and the sales were not at the reporting person's discretion.

What role does the reporting person hold at AMLX?

The reporting person, Gina Mazzariello, is listed as the company's Chief Legal Officer.
Amylyx Pharmaceuticals

NASDAQ:AMLX

AMLX Rankings

AMLX Latest News

AMLX Latest SEC Filings

AMLX Stock Data

1.42B
89.98M
9.5%
94.68%
9.43%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE